お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
936176

癌抗体薬物複合体(ADC)の世界市場:価格、投与量、治験孝察(2026年)

Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026

出版日: | 発行: KuicK Research | ページ情報: 英文 510 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

癌抗体薬物複合体(ADC)の世界市場:価格、投与量、治験孝察(2026年)
出版日: 2020年05月12日
発行: KuicK Research
ページ情報: 英文 510 Pages
納期: 即日から翌営業日
担当者のコメント
癌抗体薬物複合体(ADC)のパイプライン動向に着目した調査レポートになります。各種薬剤別の投与量や価格動向の分析もカバーしており、2026年度までの市場予測をまとめております。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートのハイライト:

  • 世界の癌抗体薬物複合体(ADC)パイプライン:297の薬物
  • 上市されている癌抗体薬物複合体:9つの医薬品
  • 抗体薬物複合体の市場機会: 2026年までに130億米ドル以上
  • 薬物試験の大部分はセカンドラインセラピー以上のものです
  • 米国が癌ADC臨床試験情勢を主導180以上の薬
  • チューブリンモジュレーターが癌ADC試験を支配:60以上の薬物
  • 販売、市場機会、臨床試験グラフ:100以上のグラフ

世界の癌抗体薬物複合体市場は、目覚しい成長を遂げており、抗癌治療薬市場の開発に関与する製薬会社に未踏の可能性を提供しています。この新薬クラスは、乳癌、急性白血病、およびリンパ腫の患者の間で、単剤療法および併用療法の形で広く受け入れられています。市場の主要企業によって採用されているさまざまな戦略に加えて、レポートはまた、成果、貴重なハイライト、および市場で行われたすべての進歩的な編集に関する情報を提供しています。

当レポートでは、世界の癌抗体薬物複合体(ADC)市場について調査し、抗体薬物複合体(ADC)の概要、今後の見通しと商業的側面、臨床パイプライン、上市薬、入手性・価格・投与量・売上分析の考察、主要企業の概要など体系的な情報を提供しています。

目次

第1章 抗体薬物複合体(ADC)のイントロダクション

  • 概要
  • ADCの歴史的動向

第2章 抗体薬物複合体の進化

  • ADCの進歩
    • 初代
    • 第2世代
    • 第三世代
  • ADCのコンポーネント
    • モノクローナル抗体(mAbs)
    • リンカー
    • ペイロード

第3章 抗体薬物複合体-作用機序

  • 抗原-抗体相互作用
  • ペイロードの解放
  • 細胞毒性のメカニズム

第4章 抗体薬物複合体の必要性

第5章 癌管理におけるADCの役割

  • 乳癌
  • 白血病
  • リンパ腫
  • その他の癌

第6章 市場分析

  • 概要
  • 現在の市場シナリオ
  • ADC市場セグメンテーション
    • 地域セグメンテーション
    • 製品別セグメンテーション

第7章 世界市場の考察

  • 米国
  • 欧州
    • ドイツ
    • ベルギー
    • フランス
    • 英国
  • 日本
  • 中国
  • インド
  • 韓国

第8章 抗体薬物複合体-可用性、投与量、価格分析

  • Mylotarg(ジェムツズマブオゾガマイシン)
  • アドセトリス(ブレンツキシマブベドチン)
  • カドシラ(トラスツズマブエンタンシン)
  • Besponsa(イノツズマブオゾガマイシン)
  • ルモキシティ(Moxetumomab pasudotox)
  • Polivy(ポラツズマブベドチン)
  • Enhertu(Fam-Trastuzumab Deruxtecan-Nxki)
  • Padcev(Enfortumab Vedotin)

第9章 抗体薬物複合体-売上考察

  • カドシラ
  • アドセトリス
  • ポリヴィ

第10章 抗体薬物複合体-臨床パイプライン考察2020年~2026年

  • フェーズ別
  • 適応症別
  • 企業別
  • 患者セグメント別
  • 国別
  • 作用機序別

第11章 企業、適応症およびフェーズ別世界の癌治療複合体臨床パイプライン

  • 調査
  • 前臨床
  • 臨床
  • フェーズ0
  • フェーズI
  • フェーズI / II
  • フェーズII
  • フェーズII / III
  • フェーズIII
  • 事前登録
  • 登録済み

第12章 市販の癌治療複合体治験考察

  • アドセトリス
  • マイロターグ
  • Junovan / Mepact
  • カドシラ
  • ベスポンサ
  • ゼバリン/ゼバマブ
  • LUMOXITI
  • OncoScint CR / OV
  • エンヘルトゥ

第13章 世界の癌抗体薬物複合体市場力学

  • 有利なパラメータ
  • 市場の課題

第14章 市場の将来展望

第15章 競合情勢

  • AstraZeneca plc
  • Genentech
  • Roche
  • 武田薬品工業
  • Pfizer
  • Oxford BioTherapeutics
  • Heidelberg Pharma
  • Synthon
  • Mersana Therapeutics
  • Progenics Pharmaceuticals
  • アステラス製薬
  • Bristol Mayer Squibb
  • Seattle Genetics
  • Immunogen
  • Celldex Therapeutics
図表

List of Figures

  • Figure 1-1: Historical Development of Antibody-Drug Conjugate
  • Figure 1-2: Approval History of Commercially Available Antibody-Drug Conjugates
  • Figure 2-1: Classification of Antibody-Drug Conjugates
  • Figure 2-2: Components of Antibody-Drug Conjugates
  • Figure 2-3: Antigen Expression Analyzing Techniques used in Development of ADCs
  • Figure 2-4: Isotypes of Monoclonal Antibodies used in ADC Development
  • Figure 2-5: Classification of Linkers
  • Figure 2-6: Types of Cleavable Linkers
  • Figure 2-7: Non-Cleavable Linker Used in ADCs Development
  • Figure 2-8: Cytotoxic Drugs Used in Antibody Drug Conjugates
  • Figure 3-1: General Mechanism of Antibody Drug Conjugates against Cancer
  • Figure 3-2: ADCs - Antigen-Antibody Interaction in Normal & Cancerous Cells
  • Figure 3-3: Releasing Mechanism of Payloads
  • Figure 3-4: Mechanism of Cytotoxicity via Alkylating Agents
  • Figure 3-5: Mechanism of Toxicity via Tubulin Inhibitors
  • Figure 4 1: Therapeutic Index - Antibody Drug Conjugate vs. Cytotoxic Drug
  • Figure 6-1: Global - Number of Breast Cancer Cases & HER2+ Breast Cancer Cases (Million), 2018
  • Figure 6-2: Global - Number of HER2+ Breast Cancer Cases vs. Other Breast Cancer (%), 2018
  • Figure 6-3: Survival Rate at Different Stages of Breast Cancer (%)
  • Figure 6-4: Global - Newly Diagnosed ALL Cases & Deaths, 2019
  • Figure 6-5: Global - Newly Diagnosed AML Cases & Deaths, 2019
  • Figure 6-6: Global - Newly Diagnosed Non-Hodgkin Lymphoma Cases & Deaths, 2019
  • Figure 6-7: Global - Newly Diagnosed AML Cases & Deaths, 2019
  • Figure 6-8: Global - Cancer Drug Market - Total vs. ADCs (US$ Billion), 2019
  • Figure 6-9: Global - Cancer Drug Market - ADCs vs. Others (US$ Billion), 2019
  • Figure 6-10: Global - Antibody Drug Conjugates Market Size (US$ Billion), 2018 & 2019
  • Figure 6-11: Global - Antibody Drug Conjugates Market Opportunity (US$ Billion), 2019 - 2026
  • Figure 6-12: Global - Antibody Drug Conjugate Regional Market Share (%), 2019
  • Figure 6-13: Global - Antibody Drug Conjugate Market Size - Total vs. Kadcyla (US$ Billion), 2019
  • Figure 6-14: Global - Antibody Drug Conjugate Market Share (%) - Kadcyla vs. Others, 2019
  • Figure 6-15: Global - Antibody Drug Conjugate Market Share (%) - Adcetris vs. Others, 2019
  • Figure 6-16: Global - Antibody Drug Conjugate Market Segmnetation by Product (%), 2019
  • Figure 7-1: US- Cancer Statistics (Million), 2018
  • Figure 7-2: US - Clinical Trial Status for Cancer Antibody Drug Conjugates, 2020
  • Figure 7-3: Europe - Cancer Statistics (Million), 2018
  • Figure 7-4: Germany - Cancer Statistics (Million), 2018
  • Figure 7-5: Belgium - Cancer Statistics, 2018
  • Figure 7-6: France - Cancer Statistics (Million), 2018
  • Figure 7-7: United Kingdom - Cancer Statistics (US$ Million), 2018
  • Figure 7-8: Japan - Cancer Death Statistics (%), 2018
  • Figure 7-9: Japan - Clinical Trial Status, 2020
  • Figure 7-10: Japan - Amount Paid by Company vs. Insured (%),
  • Figure 7-11: China - Cancer Statistics (Million), 2018
  • Figure 7-12: China - Clinical Trials for Cancer Antibody Drug Conjugate Drugs, 2020
  • Figure 7-13: China - Reimbursement Status Company vs. Insured (%), 2020
  • Figure 7-14: India - Cancer Statistics (Million), 2018
  • Figure 7-15: India - Research & Development Spending by Pharmaceutical Companies (US$ Million), 2018
  • Figure 7-16: South Korea - Cancer Statistics (Million), 2018
  • Figure 7-17: South Korea - Clinical Trial Status, 2018
  • Figure 8-1: Commercially Available Antibody Drug Conjugates
  • Figure 8-2: Mylotarg - FDA Approval, Withdrawal & Re-Approval Year
  • Figure 8-3: Mylotarg - Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
  • Figure 8-4: Mylotarg - Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), December'2019
  • Figure 8-5: Mylotarg - Recommended Number of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML, December'2019
  • Figure 8-6: Mylotarg - Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days), December'2019
  • Figure 8-7: Mylotarg - Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2), December'2019
  • Figure 8-8: Mylotarg - Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US$), December'2019
  • Figure 8-9: Mylotarg - Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, December'2019
  • Figure 8-10: Adcetris - Patent Issue & Expiration Year
  • Figure 8-11: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks), December'2019
  • Figure 8-12: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US$), December'2019
  • Figure 8-13: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (Weeks), December'2019
  • Figure 8-14: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (US$), December'2019
  • Figure 8-15: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), December'2019
  • Figure 8-16: Adcetris - Duration of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (Weeks), December'2019
  • Figure 8-17: Adcetris - Maximum Cost of Single Treatment Cycle & Full Treatment of Relapsed Primary Cutaneous ALCL or CD30-Expressing MF (US$), December'2019
  • Figure 8-18: Kadcyla - FDA Approval Year for Late Stage & Early Stage HER2+ Breast Cancer
  • Figure 8-19: Kadcyla - Price for Single Unit of 100mg & 150mg Intravenous Powder for Injection (US$), December'2019
  • Figure 8-20: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks), December'2019
  • Figure 8-21: Kadcyla - Average Cost of Single Treatment Cycle & Full Treatment of Early Stage HER2 Breast Cancer in Human with Average Weight (US$), December'2019
  • Figure 8-22: Kadcyla - Recommended Dose After 1st & 2nd Dose Reduction (mg/m2), December'2019
  • Figure 8-23: Besponsa - Orphan Market Exclusivity Issue & Expiration Year
  • Figure 8-24: Besponsa - Duration of Initial Treatment Cycle & Subsequent Cycles (Days), December'2019
  • Figure 8-25; Besponsa - Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m2), December'2019
  • Figure 8-26: Besponsa - Cost of Single Unit & Full Cost of Initial Treatment Cycle (US$), December'2019
  • Figure 8-27: Besponsa - Cost of Single Unit & Full Cost of Subsequent Treatment Cycle in Patient with CR (US$), December'2019
  • Figure 8-28: Besponsa - Cost of Single Unit & Full Cost of Subsequent Treatment Cycle in Patient with CR (US$), December'2019
  • Figure 8-29: Besponsa - Duration of Treatment of ALL - After & Without HSCT (Weeks), December'2019
  • Figure 8-30: Besponsa - Full Treatment Cost of ALL Patients with & Without Complete Remission after HSCT (US$), December'2019
  • Figure 8-31: Lumoxiti - Year of Orphan Designation, FDA Approval & Patent Expiration
  • Figure 8-32: Lumoxiti - Duration of Single Treatment Cycle & Full Treatment (Weeks), December'2019
  • Figure 8-33: Lumoxitin - Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), 2019
  • Figure 8-34: Polivy - Patent Issue & Expiration Year
  • Figure 8-35: Polivy - Duration of Single Treatment Cycle & Full Treatment (Weeks), December'2019
  • Figure 8-36: Polivy - Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US$), 2019
  • Figure 8-37: Bendamustine - Price for Single Unit & 4ml of 25mg/ml Bendamustine Intravenous Solution for Injection (US$), December'2019
  • Figure 8-38: Rituximab - Price for 1ml & 10ml of 10mg/ml Rituximab Intravenous Solution for Injection (US$), December'2019
  • Figure 8-39: Enhertu - FDA Priority Review & Approval Year
  • Figure 8-40: Enhertu - Disease Control, Tumor Shrinkage & Disease Elimination Rate (%)
  • Figure 8-41: Enhertu - Average Cost of Single Treatment Cycle & Annual Treatment Cost of Breast Cancer (US$), March'2020
  • Figure 8-42: Enhertu - Recommended Dose & Dose after Reduction (mg/Kg), March'2020
  • Figure 8-43: Enhertu - Estimated Sales Value (US$ Million), 2020 & 2026
  • Figure 8-44: Padcev - Price for 20mg & 30mg Intravenous Powder for Injection (US$), March'2020
  • Figure 8-45: Padcev - Average Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), March'2020
  • Figure 9-1: Kadcyla - Global Annual Sales Value (US$ Million), 2016 - 2019
  • Figure 9-2: Kadcyla - Global Sales Value by Quarter (US$ Billion), 2018
  • Figure 9-3: Kadcyla - Regional Sales Value (US$ Million), 2018
  • Figure 9-4: Kadcyla - Share of Sales Value by Region (%), 2018
  • Figure 9-5: Kadcyla - Sales Value by Region (US$/CHF Million), 2019
  • Figure 9-6: Kadcyla - Share of Sales Value by Region (%), 2019
  • Figure 9-7: Kadcyla - Global Sales Value of Q1 (US$ Million), 2016 - 2019
  • Figure 9-8: Kadcyla - Quarterly Sales Value (US$ Million), 2019
  • Figure 9-9: North America - Adcetris Sales Value (US$ Million), 2016 - 2019
  • Figure 9-10: North America - Adcetris Half Year Sales Value (US$ Million), 2018 & 2019
  • Figure 9-11: North America - Adcetris Quarterly Sales Value (US$ Million), 2019
  • Figure 9-12: North America - Adcetris Sales Value by Quarters (US$ Million), 2018
  • Figure 9-13: Polivy - Quarterly Sales Value (US$/CHF Million), Q3 & Q4, 2019
  • Figure 10-1: Global - Antibody Drug Conjugate Clinical Pipeline by Phase (Numbers), 2020 till 2026
  • Figure 10-2: Global - Antibody Drug Conjugate Clinical Pipeline by Phase (%),2020 till 2026
  • Figure 10-3: Global - Antibody Drug Conjugate Clinical Pipeline by Indication, 2020 till 2026
  • Figure 10-4: Global - Antibody Drug Conjugate Clinical Pipeline by Company, 2020 till 2026
  • Figure 10-5: Global - Antibody Drug Conjugate Clinical Pipeline by Patient Segment, 2020 till 2026
  • Figure 10-6: Global - Antibody Drug Conjugate Clinical Pipeline by Country, 2020 till 2026
  • Figure 10-7: Global - Antibody Drug Conjugate Clinical Pipeline by Company, 2020 till 2026
  • Figure 13-1: Antibody Drug Conjugates Market Drivers
  • Figure 13-2: Challenges for Antibody Drug Conjugates Market
目次

"Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights:

  • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs
  • Marketed Cancer Antibody Drug Conjugate: 9 Drugs
  • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026
  • Majority of Drug Trials Are For Second Line Therapy Or Greater
  • USA Dominates Cancer ADC Clinical Trials Landscape: > 180 Drugs
  • Tubulin Modulators Dominates Cancer ADC Trials: > 60 Drugs
  • Sales, Market Opportunity, Clinical Trials Graphs: > 100 Graphs

"Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" offers comprehensive clinical and non clinical insight on the recent trends and the opportunities that the market has been experiencing at a regional and at global level. The cancer antibody drug conjugate market has been witnessing tremendous growth and offers unexplored potential to pharmaceutical companies involved in development of anti cancer therapeutics market. This new drug class is widely accepted in the form of monotherapy as well as combinational therapy among the Breast Cancer, Acute Leukemia and Lymphoma patients. In addition to the various strategies that have been employed by the major key players of the market, the report also delivers information regarding the achievements, valuable highlights and all the progressive compilations that have been made in the market.

After the approval of first ADC i.e. Pfizer's Mylotarg in year 2000, the antibody drug conjugates are continuously witnessing exponential growth and are emerging as most prominent therapeutic approach for the management of cancer. After the withdrawal of Mylotarg, two new antibody drug conjugates entered into the market, which took the market to the next level. Further, the Mylotarg was also reintroduced into the market in 2017 and currently 9 cancer antibody drug conjugates are available in the market, which are continuously boosting the drug conjugates market.

The drugs launched under antibody drug conjugates class have been designed in a way such that they show promising targeting activity. The drugs incorporate antibody specificity as well as cell killing activity of cytotoxic agents that have been chemically conjugated. Other than the efficient targeting activity, the drugs under it have been prominent in showing various other clinical applications. With 9 antibody drug conjugates available in the market and all being tremendously successful, namely Lumoxiti, Polivy, Mylotarg, Besponsa, Kadcyla and Adcetris, this therapeutic method have been classified as a potent treatment in oncology.

An advantage that is associated with this class of therapeutics is that it has the ability to effectively identify the cells that are foreign or not healthy. In the present scenario, all the clinicians, non-clinicians and the patients are getting inclined towards it as it has overcome the challenge that were highlighted during other treatment procedure i.e. toxicity related issues. The current trend that the market states is that this novel therapeutic regimen has now become a part of mainstream oncology healthcare system and has achieved significant warmth in the oncology department all around the globe.

As per report findings, the cancer antibody drug conjugates will shown tremendous success in the upcoming years in both the research and market segments. The continuous success of the approved cancer antibody drug conjugates and presence of many new antibody drug conjugates in the clinical pipeline is indicating a very bright future for this market. The challenges for this market are very few, which can be easily prevail over in a short period of time and the driving factors such as unmet medical demand and high prevalence of cancer, are continuously boosting the market growth. We believe that in upcoming years, the antibody drug conjugates will occupy a dominant share in overall oncology market and it will emerge as most prominent cancer therapeutic segment.

Table of Contents

1. Introduction to Antibody Drug Conjugates (ADCs)

  • 1.1 Overview
  • 1.2 Historical Development of ADCs

2. Evolution of Antibody Drug Conjugates

  • 2.1 Advancements in ADCs
    • 2.1.1 First Generation
    • 2.1.2 Second-Generation
    • 2.1.3 Third Generation
  • 2.2 Components of ADCs
    • 2.2.1 Monoclonal Antibodies (mAbs)
    • 2.2.2 Linkers
    • 2.2.3 Payloads

3. Antibody Drug Conjugates - Mechanism of Action

  • 3.1 Antigen - Antibody Interaction
  • 3.2 Release of Payload
  • 3.3 Mechanism of Cytotoxicity

4. Need of Antibody Drug Conjugates

5. Role of ADCs in Cancer Management

  • 5.1 Breast Cancer
  • 5.2 Leukemia
  • 5.3 Lymphoma
  • 5.4 Other Cancers

6. Antibody Drug Conjugate Market Analysis

  • 6.1 Overview
  • 6.2 Current Market Scenario
  • 6.3 ADCs Market Segmentation
    • 6.3.1 Regional Segmentation
    • 6.3.2 Segmentation By Products

7. Global - Cancer Antibody Drug Conjugate Market Insights

  • 7.1 US
  • 7.2 Europe
    • 7.2.1 Germany
    • 7.2.2 Belgium
    • 7.2.3 France
    • 7.2.4 United Kingdom
  • 7.3 Japan
  • 7.4 China
  • 7.5 India
  • 7.6 South Korea

8. Antibody Drug Conjugates - Availability, Dosage & Price Analysis

  • 8.1 Mylotarg (Gemtuzumab ozogamicin)
  • 8.2 Adcetris (Brentuximab vedotin)
  • 8.3 Kadcyla (Trastuzumab emtansine)
  • 8.4 Besponsa (Inotuzumab ozogamicin)
  • 8.5 Lumoxiti (Moxetumomab pasudotox)
  • 8.6 Polivy (Polatuzumab vedotin)
  • 8.7 Enhertu (Fam-Trastuzumab Deruxtecan-Nxki)
  • 8.8 Padcev (Enfortumab Vedotin)

9. Antibody Drug Conjugates - Sales Insight

  • 9.1 Kadcyla
  • 9.2 Adcetris
  • 9.3 Polivy

10. Antibody Drug Conjugates - Clinical Pipeline Insight 2020 - 2026

  • 10.1 By Phase
  • 10.2 By Indication
  • 10.3 By Company
  • 10.4 By Patient Segment
  • 10.5 By Country
  • 10.6 By Mechanism of Action

11. Global Cancer Drug Conjugates Clinical Pipeline By Company, Indication & Phase

  • 11.1 Research
  • 11.2 Preclinical
  • 11.3 Clinical
  • 11.4 Phase-0
  • 11.5 Phase-I
  • 11.6 Phase-I/II
  • 11.7 Phase-II
  • 11.8 Phase-II/III
  • 11.9 Phase-III
  • 11.10 Preregistration
  • 11.11 Registered

12. Marketed Cancer Drug Conjugates Clinical Insight

  • 12.1 Adcetris
  • 12.2 Mylotarg
  • 12.3 Junovan/Mepact
  • 12.4 Kadcyla
  • 12.5 Besponsa
  • 12.6 Zevalin/ Zevamab
  • 12.7 LUMOXITI
  • 12.8 OncoScint CR/OV
  • 12.9 Enhertu

13. Global Cancer an Antibody Drug Conjugates Market Dynamics

  • 13.1 Favorable Parameters
  • 13.2 Challenges for Antibody Drug Conjugates Market

14. Antibody Drug Conjugates Market - Future Outlook

15. Competitive Landscape

  • 15.1 AstraZeneca plc
  • 15.2 Genentech
  • 15.3 Roche
  • 15.4 Takeda Pharmaceuticals
  • 15.5 Pfizer
  • 15.6 Oxford BioTherapeutics
  • 15.7 Heidelberg Pharma
  • 15.8 Synthon
  • 15.9 Mersana Therapeutics
  • 15.10 Progenics Pharmaceuticals
  • 15.11 Astellas Pharma
  • 15.12 Bristol Mayer Squibb
  • 15.13 Seattle Genetics
  • 15.14 Immunogen
  • 15.15 Celldex Therapeutics
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.